MMED Profile
- Sector: Health Technology
- Industry: Biotechnology
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Stanley D. Glick, and Jamon Alexander Rahn in 2019 and is headquarter in Toronto, Canada.
[bbp-topic-index]
[bbp-topic-form]
Recent News
- Lexaria Bioscience Granted First European Patent for DehydraTECH Technology
- Tetra Bio-Pharma Acquires Exclusive Global Technology Rights to a Mucoadhesive Delivery Technology Called Adversa(R) for its PPP-002 (dronabinol) drug candidate from IntelGenx
- Avicanna Announces Results of Annual General and Special Meeting
- Meta Growth Announces Strong Support and Board Nominees in Connection with Proposed Arrangement with High Tide
- 4Front Ventures Corp. Announces C$15 Million Bought Deal Public Offering
- Delta 9 Announces Normal Course Issuer Bid for Common Shares and Convertible Debentures
- NeonMind Superfood Mushroom Coffee Update
- Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
- 1933 Industries Partners with Orchid Ventures to Launch the Orchid Essentials Brand in Nevada
- Wildflower Brands Enters Hong Kong Luxury Retail Market Through Lane Crawford
